ADXS - Advaxis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.44
+0.10 (+7.46%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.34
Open1.34
Bid1.25 x 900
Ask1.60 x 4000
Day's Range1.31 - 1.51
52 Week Range1.15 - 7.45
Volume2,082,902
Avg. Volume762,357
Market Cap75.775M
Beta3.69
PE Ratio (TTM)N/A
EPS (TTM)-2.08
Earnings DateSep 10, 2018 - Sep 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.50
Trade prices are not sourced from all markets
  • ACCESSWIRE19 hours ago

    Biotech Companies with Great Futures

    Microcapspeculators.com is an informational website that is highly interested in exploring development stage companies, enroute to finding companies with the best potential. HENDERSON, NV / ACCESSWIRE ...

  • Why Advaxis Stock Is Soaring Today
    Market Realist4 days ago

    Why Advaxis Stock Is Soaring Today

    Today, Advaxis (ADXS) is trading at $1.43, which represents a rise of ~16.80% from yesterday’s close of $1.22. On July 12, Advaxis stock closed at $1.22 and hit its 52-week low of $1.15. Advaxis hit its 52-week high of $7.45 on September 11, 2017. Today, the FDA lifted its clinical hold on Advaxis’s IND (Investigational New Drug) application for the initiation of its Phase 1/2 trial of a combination therapy of axalimogene filolisbac and AstraZeneca’s (AZN) Imfinzi (duravalumab).

  • Benzinga4 days ago

    Advaxis Shares Soar After FDA Lifts Clinical Hold On Cancer Drug

    Shares of the late-stage immuno-oncology company Advaxis, Inc. (NASDAQ: ADXS) are adding about one-fifth of their value in the wake of a positive regulatory announcement. The FDA lifted the clinical hold it previously placed on the company's investigational new drug application for its axalimogene filolisbac in combination with durvalumab to treat patients with advanced, recurrent or refractory cervical cancer and HPV-associated head and neck cancer, according to Advaxis. The FDA imposed a clinical hold March 9 following a safety report of a patient death that occurred Feb. 27 after dosing.

  • MarketWatch4 days ago

    Advaxis shares rise 68% after FDA lifts clinical hold on its drug trial

    Shares of the biotech company Advaxis Inc. (ADXS) surged 68% in premarket trade on Friday after the Food and Drug Administration lifted a clinical hold on the company's phase 1/2 study for a cancer drug combination. The trial is testing a combination of Advaxis' axalimogene filolisbac, a listeria-based immunotherapy, and Astrazeneca's durvalumab (AZN) for patients with advanced, recurrent or refractory cervical cancer and HPV-associated head and neck cancer.

  • Business Wire4 days ago

    Advaxis Announces FDA Lifts Clinical Hold on Phase 1/2 Combination Study of Axalimogene Filolisbac with Durvalumab

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company’s Investigational New Drug (IND) application for its Phase 1/2 study of axalimogene filolisbac (AXAL) in combination with durvalumab for the treatment of patients with advanced, recurrent or refractory cervical cancer and HPV-associated head and neck cancer.

  • Business Wire7 days ago

    Advaxis Provides Update on MAA Filing and ADXS-HOT Program

    Advaxis’ regulatory action in Europe is based on European Medicines Agency (EMA) feedback following its initial review indicating the application will likely need additional data to support a conditional approval. As previously communicated, Advaxis is actively seeking a partner to support the late-stage cervical cancer program.

  • GlobeNewswire19 days ago

    New Research Coverage Highlights Knowles, Advaxis, G-III Apparel Group, LTD, National CineMedia, Haemonetics, and MACOM Technology Solutions — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, June 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Knowles ...

  • Thomson Reuters StreetEvents29 days ago

    Edited Transcript of ADXS earnings conference call or presentation 7-Jun-18 3:00pm GMT

    Q2 2018 Advaxis Inc Earnings Call

  • Business Wirelast month

    Advaxis Announces Dosing of First Patient with ADXS-NEO, an Investigational Customized Immunotherapy Approach Targeting Personal Neoantigens

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced it has commenced a Phase 1 trial with the dosing of the first patient with ADXS-NEO, an investigational personalized immunotherapy approach targeting personal neoantigens found by sequencing a patient’s own cancer cells. ADXS-NEO is being evaluated in an open-label, dose-escalation, multicenter Phase 1 clinical trial in the United States. The study is open to patients with metastatic non-small cell lung cancer (NSCLC), metastatic microsatellite stable colon cancer and metastatic squamous head and neck cancer.

  • Associated Presslast month

    Advaxis: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the Princeton, New Jersey-based company said it had a loss of 27 cents. The biotechnology company posted revenue of $1.7 million in the period. The company's shares closed at $1.71. ...

  • Business Wirelast month

    Advaxis Announces Prioritization of Product Portfolio and Reports Fiscal 2018 Second Quarter Financial Results

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a new prioritization of its product portfolio, as well as financial results and business highlights for the three months ended April 30, 2018. The product portfolio review was conducted under the leadership of recently appointed President and CEO Ken Berlin, along with the full Advaxis executive team including recently named Chief Medical Officer Andres Gutierrez, M.D., Ph.D. The process reflects a commitment to allocate capital to programs that meet three criteria: (i) commercially attractive applications for the company’s Lm technology platform, (ii) the opportunity for the Lm platform to meaningfully impact cancer care, and (iii) a rapid and cost-effective route to generate clinical and immunological response data to demonstrate proof of concept.

  • ACCESSWIRElast month

    Complimentary Technical Snapshots on Adverum Biotechnologies and Three More Biotech Stocks

    Featured today on WallStEquities.com is the Biotechnology industry, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. Under evaluation this morning are four equities: Adaptimmune Therapeutics PLC (NASDAQ: ADAP), Aduro BioTech Inc. (NASDAQ: ADRO), Advaxis Inc. (NASDAQ: ADXS), and Adverum Biotechnologies Inc. (NASDAQ: ADVM).

  • Business Wirelast month

    Advaxis Appoints Molly Henderson as Chief Financial Officer

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the appointment of Molly Henderson as Executive Vice President and Chief Financial Officer, effective June 6, 2018. Ms. Henderson joins Advaxis from Cedar Cliff, LLC, where she served as a financial and business consultant to high-growth entrepreneurial companies. Previously she was Chief Financial Officer at Iovance Biotherapeutics, Inc. (formerly Lion Biotechnologies, Inc.) (IOVA), an immuno-oncology company where she was responsible for all financial, SEC reporting, legal, governance, human resources and IT-related functions, and raised $100 million in equity capital.

  • Business Wire2 months ago

    Data Highlighting Advaxis’ ADXS-PSA Presented at ASCO Annual Meeting

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced preliminary data from the ongoing metastatic, castration resistant prostate cancer (mCRPC) Phase 1/2 KEYNOTE-046 study, conducted in conjunction with Merck (known as MSD outside the United States and Canada) evaluating ADXS-PSA, Advaxis’s Listeria monocytogenes (Lm)-based immunotherapy, alone and in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.

  • Business Wire2 months ago

    Advaxis to Host Business Update and Second Quarter 2018 Financial Results Conference Call on June 7, 2018

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced today the upcoming release of financial results for the six months ended April 30, 2018, to take place on Thursday, June 7, 2018. Advaxis’ senior management will host a conference call to review its financial results and provide a business update. The conference call and live audio webcast will begin at 11:00 a.m. Eastern time on Thursday, June 7, 2018.

  • GlobeNewswire2 months ago

    Analysis: Positioning to Benefit within Advaxis, e.l.f. Beauty, Heron Therapeutics, PVH, Energy Recovery, and A. O. Smith — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, May 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Advaxis, ...

  • Business Wire2 months ago

    Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, provides an update on recently presented preclinical data demonstrating the anti-cancer potential of their Lm vector that presents tumor neoantigens, and is being evaluated in the ADXS-NEO program. ADXS-NEO is derived from the Company’s proprietary Lm Technology and is being developed in partnership with Amgen. These preclinical findings were discussed in poster presentations at the recent American Association for Cancer Research (AACR) Annual Meeting.

  • Advaxis Announces Executive Leadership Changes
    Business Wire3 months ago

    Advaxis Announces Executive Leadership Changes

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A.

  • Business Wire3 months ago

    Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting

     Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of ADXS-HOT preclinical data in a poster discussion entitled “Targeting Shared Hotspot Cancer Mutations with a Listeria monocytogenes Immunotherapy Induce Potent Anti-Tumor Immunity” at the American Association for Cancer Research Annual ...

  • What Is The Future Prospect For Healthcare And Advaxis Inc (NASDAQ:ADXS)?
    Simply Wall St.3 months ago

    What Is The Future Prospect For Healthcare And Advaxis Inc (NASDAQ:ADXS)?

    Advaxis Inc (NASDAQ:ADXS), a US$83.18M small-cap, operates in the healthcare industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as an aging population, impactingRead More...

  • Business Wire3 months ago

    Data Highlighting Advaxis’ ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Meeting

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that The American Society of Clinical Oncology has accepted the abstract titled “ADXS-PSA plus pembrolizumab in metastatic castration-resistant prostate cancer ” for a poster discussion at their annual meeting to be held June 1-5, 2018 in Chicago.

  • ACCESSWIRE4 months ago

    Wired News – Recro Pharma Publishes Data from Phase-III Trial for IV Meloxicam

    Stock Monitor: Advaxis Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 29, 2018 / Active-Investors.com has just released a free research report on Recro Pharma, Inc. (NASDAQ: REPH ). If you want ...

  • Advaxis Inc (NASDAQ:ADXS): Does The -36.80% Earnings Drop Reflect A Longer Term Trend?
    Simply Wall St.4 months ago

    Advaxis Inc (NASDAQ:ADXS): Does The -36.80% Earnings Drop Reflect A Longer Term Trend?

    Examining Advaxis Inc’s (NASDAQ:ADXS) past track record of performance is a useful exercise for investors. It allows us to reflect on whether the company has met or exceed expectations, whichRead More...

  • Business Wire4 months ago

    Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that results from multiple preclinical studies of its Lm-based antigen delivery technology will be presented at the American Association for Cancer Research Annual Meeting 2018 , April 14-18, 2018 in Chicago.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of ADXS earnings conference call or presentation 12-Mar-18 8:30pm GMT

    Q1 2018 Advaxis Inc Earnings Call